Durable Responses to Atezolizumab Plus Bevacizumab in HCC

Saadvik Raghuramy shared a post on X about a recent paper by Ying-Chun Shen et al. published in JCO.

“Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab”

Authors: Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, Masatoshi Kudo, Ann-Lii Cheng et al.

“HCC Patients achieving a durable response with ATEZO/BEV i.e. a PR or SD tend to have much more favourable outcome.

• mOS not estimatable for patients with durable PR
• mOS 23.7 months for durable SD
• pCR more frequent with PR (57%).”

Source: Saadvik Raghuramy/X

Saadvik Raghuramy is the Head of the Department of Medical Oncology at Arete Hospitals. Dr. Saadvik specializes in treating a wide range of cancers, including breast, stomach, colorectal, liver, esophageal, prostate, kidney, bladder, oral, brain tumors, and lung cancers.

His clinical expertise includes immunotherapy, monoclonal antibody therapy, chemotherapy, cancer screening, palliative care, targeted therapy, clinical trials, cancer genetic counseling, and hormone therapy.